A second‐generation CD38‐CAR‐T cell for the treatment of multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an aggressive plasma cell malignancy, causing a number of deaths worldwide every year. Chimeric antigen receptor (CAR) transduced T‐cell therapy has been a promising immunotherapy against hematological malignancies. METHODS: In this study, we developed a second‐g...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hongwen, Li, Jing, Wu, Jiazhuo, Shi, Zhuangzhuang, Gao, Yuyang, Song, Wenting, Li, Jiwei, Li, Zhaoming, Zhang, Mingzhi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225187/
https://www.ncbi.nlm.nih.gov/pubmed/37039305
http://dx.doi.org/10.1002/cam4.5818

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10225187/
https://www.ncbi.nlm.nih.gov/pubmed/37039305
http://dx.doi.org/10.1002/cam4.5818

Ejemplares similares